DiaMedica Therapeutics Inc.Company Review & Valuation

DMCAF
OTC Markets

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acutShow moree ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Show less

Industry
Biotechnology
HQ Location
Minneapolis, Minnesota

Stock Price

Price data not available for DiaMedica Therapeutics Inc..

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

Biogen
Alexion Pharmaceuticals
MannKind Corporation
Arena Pharmaceuticals

back to top